Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.

Autor: Bordalo Ferreira, Filipa1 (AUTHOR) filipa.b.ferreira@hff.min-saude.pt, Rafael, Maria Ana1 (AUTHOR), Coimbra, Lúcia2 (AUTHOR), Boavida, Nazaré2 (AUTHOR), Arrobas, Fernando3 (AUTHOR), Pereira Correia, Fábio1 (AUTHOR), Martins Figueiredo, Luísa1 (AUTHOR), Carvalho e Branco, Joana1 (AUTHOR), Carvalho Lourenço, Luís1 (AUTHOR), Santos, Liliana1 (AUTHOR), Oliveira, Ana Maria1 (AUTHOR)
Zdroj: Vaccine. Jun2023, Vol. 41 Issue 26, p3862-3871. 10p.
Databáze: Academic Search Ultimate
Externí odkaz: